Back to Newsroom

CombiMatrix Launches Targeted Array for Prenatal Analysis

IRVINE, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the launch of its Targeted Array for Prenatal Analysis. This new test offers the superior diagnostic power of microarray analysis for the detection of clinically relevant microdeletion and microduplication disorders, while minimizing the risk of identifying a variant of uncertain significance (VOUS) on chorionic villus sampling (CVS) and amniocentesis samples.

Click here to read more